Cargando…
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
BACKGROUND: Radiofrequency ablation (RFA) is considered as a convenient treatment with mild damage in treating recurrent hepatocellular carcinoma (RHCC). However, for patients with high risk of progression after RFA still needs new strategies to decrease the repeat recurrence. METHODS: A total of 46...
Autores principales: | Zhou, Qunfang, Wang, Xiaohui, Li, Ruixia, Wang, Chenmeng, Wang, Juncheng, Xie, Xiaoyan, Li, Yali, Li, Shaoqiang, Mao, Xianhai, Liang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392709/ https://www.ncbi.nlm.nih.gov/pubmed/35816221 http://dx.doi.org/10.1007/s00535-022-01895-3 |
Ejemplares similares
-
Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022) -
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020) -
Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021) -
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)